FinnCap Reaffirms Buy Rating for Motif Bio PLC (MTFB)
A number of other equities analysts also recently weighed in on MTFB. Northland Securities reissued a buy rating and set a GBX 90 ($1.17) target price on shares of Motif Bio PLC in a research note on Tuesday, May 2nd. Beaufort Securities reissued a speculative buy rating and set a GBX 110 ($1.43) target price on shares of Motif Bio PLC in a research note on Wednesday, May 3rd.
Shares of Motif Bio PLC (LON:MTFB) opened at 27.00 on Thursday. The company’s market capitalization is GBX 52.89 million. Motif Bio PLC has a 1-year low of GBX 21.44 and a 1-year high of GBX 57.00. The stock’s 50 day moving average price is GBX 28.86 and its 200 day moving average price is GBX 29.35.
COPYRIGHT VIOLATION NOTICE: “FinnCap Reaffirms Buy Rating for Motif Bio PLC (MTFB)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.thecerbatgem.com/2017/08/28/finncap-reaffirms-buy-rating-for-motif-bio-plc-mtfb.html.
About Motif Bio PLC
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Stock Ratings for Motif Bio PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio PLC and related stocks with our FREE daily email newsletter.